The dietary histone deacetylase inhibitor sulforaphane induces human β-defensin-2 in intestinal epithelial cells

Immunology

Volumn 125, Issue 2, 2008, Pages 241-251

  Schwab, Markus ^a   Reynders, Veerle ^a   Loitsch, Stefan ^a   Steinhilber, Dieter ^a   Schröder, Oliver ^a   Stein, Jürgen ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

defensin 2; Innate immunity; MEK ERK signalling pathway; Sulforaphane; Vitamin D receptor

Indexed keywords

BETA DEFENSIN 2; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFORAPHANE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANCER CELL; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

BETA-DEFENSINS; COLON; DIET; ENZYME INHIBITORS; EPITHELIAL CELLS; HISTONE DEACETYLASES; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PPAR GAMMA; RECEPTORS, CALCITRIOL; RNA, MESSENGER; THIOCYANATES; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 51249112155     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02834.x     Document Type: Article

References (74)

1. Wehkamp J, Stange EF. Paneth cells and the innate immune response. Curr Opin Gastroenterol 2006 22:644 50.
2. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004 4:953 64.
3. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003 3:710 20.
4. Zasloff M. Antimicrobial peptides in health and disease. N Engl J Med 2002 347:1199 200.
5. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005 77:460 5.
6. Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn's disease. Chem Immunol Allergy 2005 86:42 54.
7. Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 102:18129 34.
8. Zasloff M. Defending the epithelium. Nat Med 2006 12:607 8.
9. Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol 2004 20:82 8.
10. Bevins CL, Martin-Porter E, Ganz T. Defensins and innate host defence of the gastrointestinal tract. Gut 1999 45:911 5.
11. Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol 2005 21:147 51.
12. O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, Kagnoff MF. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999 163:6718 24.
13. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003 9:215 23.
14. Wehkamp J, Harder J, Wehkamp K et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004 72:5750 8.
15. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005 27:1337 47.
16. Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005 2:406 15.
17. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 1999 163:947 53.
18. Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005 62:784 90.
19. Markeeva N, Lisovskiy I, Lyzogubov V et al. Expression of beta-defensin-2 in human gastric tumors: a pilot study. Exp Oncol 2005 27:130 5.
20. Bullard RS, Gibson W, Bose SK et al. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol 2008 45:839 48.
21. Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res 2007 635:90 104.
22. Myzak MC, Dashwood RH. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 2006 7:443 52.
23. Myzak MC, Ho E, Dashwood RH. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 2006 45:443 6.
24. Thejass P, Kuttan G. Immunomodulatory activity of Sulforaphane, a naturally occurring isothiocyanate from broccoli (Brassica oleracea). Phytomedicine 2007 14:538 45.
25. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001 276:32008 15.
26. Bertl E, Bartsch H, Gerhauser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 2006 5:575 85.
27. Schwab M, Reynders V, Shastri Y, Loitsch S, Stein J, Schroder O. Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol Immunol 2007 44:2107 14.
28. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002 70:953 63.
29. Schauber J, Iffland K, Frisch S et al. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol 2004 41:847 54.
30. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 2006 118:509 19.
31. Jakubikova J, Sedlak J, Mithen R, Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 2005 69:1543 52.
32. Traka M, Gasper AV, Smith JA, Hawkey CJ, Bao Y, Mithen RF. Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane. J Nutr 2005 135:1865 72.
33. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 2000 39:164 71.
34. Gurnell M, Wentworth JM, Agostini M et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 2000 275:5754 9.
35. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFkappaB signalling. Mol Immunol 2007 44:3625 32.
36. Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 2006 11:1801 11.
37. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997 88:553 60.
38. Wehkamp J, Fellermann K, Herrlinger KR et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 14:745 52.
39. Fellermann K, Stange DE, Schaeffeler E et al. A chromosome 8 gene-cluster polymorphism with low human Beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006 79:439 48.
40. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006 27:344 9.
41. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 2005 70:394 406.
42. Schauber J, Svanholm C, Termen S et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 2003 52:735 41.
43. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 2004 64:5767 74.
44. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 2006 20:506 8.
45. Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee PH, Martel P, Chaumontet C. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 2004 25:1227 36.
46. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 2007, doi:. Epub ahead of print.
47. Schauber J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, Zugel U, Bikle DD, Gallo RL. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D(3). J Invest Dermatol 2007, doi:. Epub ahead of print.
48. Rahman A, Fahlgren A, Sitohy B, Baranov V, Zirakzadeh A, Hammarstrom S, Danielsson A, Hammarstrom ML. Beta-defensin production by human colonic plasma cells: a new look at plasma cells in ulcerative colitis. Inflamm Bowel Dis 2007 13:847 55.
49. Monick MM, Powers LS, Gross TJ, Flaherty DM, Barrett CW, Hunninghake GW. Active ERK contributes to protein translation by preventing JNK-dependent inhibition of protein phosphatase 1. J Immunol 2006 177:1636 45.
50. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007 86:800 11.
51. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005 26:662 87.
52. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999 20:649 88.
53. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006 291:E315 22.
54. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001 169:453 9.
55. Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 2003 127:1121 3.
56. Auwerx J. Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain? Am J Physiol Gastrointest Liver Physiol 2002 282:G581 5.
57. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004 80:1717S 20S.
58. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000 47:211 4.
59. Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004 173:2909 12.
60. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000 272:380 5.
61. Gaschott T, Stein J. Short-chain fatty acids and colon cancer cells: the vitamin D receptor - butyrate connection. Recent Results Cancer Res 2003 164:247 57.
62. Gaschott T, Werz O, Steinmeyer A, Steinhilber D, Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 2001 288:690 6.
63. Keum YS, Yu S, Chang PP et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 2006 66:8804 13.
64. Shen G, Xu C, Chen C, Hebbar V, Kong AN. p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol 2006 57:317 27.
65. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995 9:726 35.
66. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001 12:397 408.
67. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001 410:37 40.
68. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000 25:257 60.
69. Moon SK, Lee HY, Li JD et al. Activation of a Src-dependent Raf-MEK1/2-ERK signaling pathway is required for IL-1alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells. Biochim Biophys Acta 2002 1590:41 51.
70. Jang BC, Lim KJ, Paik JH et al. Up-regulation of human beta-defensin 2 by interleukin-1beta in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-kappaB. Biochem Biophys Res Commun 2004 320:1026 33.
71. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007 75:2399 407.
72. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, Schroder JM. Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics 1997 46:472 5.
73. Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 2004 21:661 70.
74. Jeong WS, Kim IW, Hu R, Kong AN. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res 2004 21:649 60.